Abstract

SARS-CoV-2, the highly transmissible and infectious novel coronavirus, is responsible for the current COVID-19 pandemic. Therapeutic efforts toward the development of a vaccine and other treatment modalities are a priority. High-affinity neutralizing antibodies play a critical role in protection against viruses so a rapid development to identify such neutralizers against SARS-CoV-2 that also cross-protect against other coronaviruses is warranted. Here, we review current research on the isolation of SARS-CoV-2 neutralizing monoclonal antibodies from B cells of convalescent patients and their effectiveness in a small animal model to limit the viral disease. The antibodies that were able to successfully treat COVID-19 in the animals were highly specific against the ACE2 binding site of the viral spike protein and thus efficiently blocked infection.

Keywords:  SARS-CoV-2, COVID-19, nAbs, ACE2, Spike protein, monoclonal antibody, antibody therapy

To cite this article: Chakraborty S; Neutralizing antibodies: Viable treatment modality for COVID-19, Biotechnology Kiosk, Vol 2, Issue 6, PP: 10-16 (2020); DOI: https://doi.org/10.37756/bk.20.2.6.1